-
Canaccord Genuity Reiterates Hold Rating on Caris Life Sciences Inc (CAI)
-
Caris Life Sciences reports 94% revenue growth for 2025
-
Increasing unusual option volume: CAI CDTX PEPG XPO INFY EXE LW FLEX USAS TGEN
-
Canaccord Genuity Starts Caris Life Sciences Inc (CAI) at Hold
-
CAI International (CAI) Reports Q3 EPS of $0.08 ; Offers Guidance
-
Evercore Adds Names to TAP Lists
-
Caris Life Sciences Inc (CAI) PT Raised to $37 at BofA Securities
-
Caris Life Sciences Inc (CAI) PT Raised to $45 at BTIG
-
Caris Life Sciences Inc (CAI) PT Raised to $40 at Evercore ISI
-
CAI International (CAI) Reports Q2 Loss of $7.97 ; Offers Guidance
-
Caris Life Sciences publishes AI breast cancer survival study
-
Caris Life Sciences publishes AI cancer diagnosis study results
-
Caris Life Sciences validates tumor-infiltrating clonal hematopoiesis findings
-
Wolfe Research Starts Caris Life Sciences Inc (CAI) at Outperform
-
Evercore ISI Starts Caris Life Sciences Inc (CAI) at Outperform
-
TD Cowen Starts Caris Life Sciences Inc (CAI) at Buy
-
Citi Starts Caris Life Sciences Inc (CAI) at Buy
-
JPMorgan Starts Caris Life Sciences Inc (CAI) at Overweight
-
Guggenheim Starts Caris Life Sciences Inc (CAI) at Buy
-
BTIG Starts Caris Life Sciences Inc (CAI) at Buy
-
BofA Securities Starts Caris Life Sciences Inc (CAI) at Buy
-
Caris Life Sciences study validates blood-based cancer detection assay
-
Caris Life Sciences (CAI) Opens at $27, IPO Priced at $21
-
Caris Life Sciences (CAI) IPO indicated to open at $30 after pricing at $21
-
Caris Life Sciences (CAI) Raises Price Range of 23.53M Share IPO at $19-$20/sh
-
Caris Life Sciences (CAI) Launches IPO
-
Caris Life Sciences (CAI) Files for 23.53M Share IPO at $16-$18/sh

